1.
Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity
by Yang, Heng
Nature medicine, 2019-09, Vol.25 (9), p.1428-1441
2.
Trends in cancer risk among people with AIDS in the United States 1980-2002
by ENGELS, Eric A
AIDS (London), 2006, Vol.20 (12), p.1645-1654
3.
4.
Toxoplasma gondii infection in cancer patients: Prevalence, risk factors, genotypes and association with clinical diagnosis
by Cong, Wei
Cancer letters, 2015, Vol.359 (2), p.307-313
5.
Immunogenic neoantigens derived from gene fusions stimulate T cell responses
by Yang, Wei
Nature medicine, 2019-05, Vol.25 (5), p.767-775
6.
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
by Turajlic, Samra
The lancet oncology, 2017-08, Vol.18 (8), p.1009-1021
7.
The microbiome and hepatobiliary-pancreatic cancers
by Mima, Kosuke
Cancer letters, 2017, Vol.402, p.9-15
8.
Current Challenges in Cancer Treatment
by Zugazagoitia, Jon, MD, PhD
Clinical therapeutics, 2016, Vol.38 (7), p.1551-1566
9.
CD8 + T cells contribute to survival in patients with COVID-19 and hematologic cancer
by Bange, Erin M
Nature medicine, 2021-07, Vol.27 (7), p.1280-1289
10.
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
by Janjigian, Yelena Y
The lancet oncology, 2020-06, Vol.21 (6), p.821-831
11.
Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma
by Donovan, Laura K
Nature medicine, 2020-05, Vol.26 (5), p.720-731
12.
Genomic correlates of response to immune checkpoint blockade
by Keenan, Tanya E
Nature medicine, 2019-03, Vol.25 (3), p.389-402
13.
Prophylactic HPV vaccines: New interventions for cancer control
by Barr, Eliav
Vaccine, 2008, Vol.26 (49), p.6244-6257
14.
DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activation
by Xiao, Qian
Nature medicine, 2018-03, Vol.24 (3), p.262-270
15.
Regulation of Tumor Metastasis by Myeloid-Derived Suppressor Cells
by Condamine, Thomas
Annual review of medicine, 2015-01-14, Vol.66 (1), p.97-110
16.
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis
by Heczey, Andras
Nature medicine, 2020-11, Vol.26 (11), p.1686-1690
17.
PD-L1 expression as a potential predictive biomarker
by Fusi, Alberto
The lancet oncology, 2015, Vol.16 (13), p.1285-1287
18.
Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort
by Hleyhel, Mira
AIDS (London), 2014-09-10, Vol.28 (14), p.2109-2118
19.
Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in
by Nowak, Anna K
The lancet oncology, 2020-09, Vol.21 (9), p.1213-1223
20.
Novel therapies for malignant pleural mesothelioma
by Scherpereel, Arnaud
The lancet oncology, 2018-03, Vol.19 (3), p.e161-e172
